Creating an organization to accelerate R&D for drug-resistant infections

Antimicrobial resistance

Creating an organization to accelerate R&D for drug-resistant infections

Together with the World Health Organization (WHO), we launched the Global Antibiotic Research and Development Partnership (GARDP) in 2016.

GARDP is a not-for-profit organization that develops new treatments to fight drug-resistant infections that pose the greatest threat to health, while working to ensure responsible use and sustainable access.

In 2019, GARDP became an independent legal entity, following a successful incubation by DNDi, during which time we provided GARDP’s initial governance, scientific environment, and infrastructure, as well as support for resource mobilization, communication, finance, and human resources.

Both organizations continue to share R&D expertise and capacity (including discovery, pharmaceutical development, translational science, pharmacovigilance, and quality assurance); access to an international network, as in-country implementation of GARDP’s programmes is supported by DNDi regional offices and through a joint office in Southern Africa; and a common approach on global health policy for promoting and contributing to public health needs-driven R&D and access.

‘We’re proud to have provided the environment to enable GARDP to kickstart its mission to deliver antimicrobial research for patients. We look forward to a strong collaboration in sharing resources and knowledge with GARDP in the future, for the ultimate benefit of the populations served by GARDP and DNDi.’

Dr Marie-Paule Kieny, DNDi Board Chair

Antibiotic-resistant infections cause nearly 1.3 million deaths each year

Antibiotics have saved millions of lives and radically improved our well-being, but they have been used so extensively that many are losing their ability to overcome bacteria.

GARDP develops and makes accessible antibiotic treatments to address the threat of drug-resistant infections.

GARDP’s key priorities

Developing antibiotic treatments for serious bacterial infections and sepsis in adults and children, as well as sexually transmitted infections. GARDP also screens thousands of compounds and natural products to discover the antibiotics of the future.
Expanding antibiotic access, including SECURE. GARDP is expanding access to antibiotics in its portfolio for appropriate use. It also developing SECURE, a collaborative initiative to improve access to essential novel and generic antibiotics.
Advancing antimicrobial R&D through education and collaboration on scientific affairs, including the online platform REVIVE.

Learn more about GARDP’s work